Kindred Biosciences, Inc.KINNASDAQ
LOADING
|||
| Metric | Q2 2020 | Q3 2020 | Q4 2020 | Q1 2021 | Q2 2021 |
|---|---|---|---|---|---|
| Revenue Growth | +3101.21% | -5.53% | -32.12% | +297.18% | -91.06% |
| Gross Profit Growth | +3574.23% | -23.52% | -53.05% | +0.00% | -92.61% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | -129.03% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -135.53% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -140.39% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -134.43% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | -135.00% |
| Weighted Average Shares Growth | +0.91% | +0.96% | +0.32% | +4.86% | +15.38% |
| Weighted Average Shares Diluted Growth | +3.08% | +0.96% | +0.32% | +4.86% | +12.95% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -110.91% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -111.91% |
| Receivables Growth | -71.93% | -7.74% | -32.39% | +5111.07% | +491.25% |
| Inventory Growth | -91.07% | -90.86% | -95.09% | -100.00% | -100.00% |
| Asset Growth | -0.97% | -16.59% | -15.97% | +18.61% | -6.10% |
| Book Value per Share Growth | -20.67% | -20.39% | -17.89% | +31.70% | -20.37% |
| Debt Growth | +1064.81% | +2.09% | +2.66% | +3.09% | +15.59% |
| R&D Expense Growth | +9.86% | +1.33% | +6.94% | -29.10% | -24.67% |
| SG&A Expenses Growth | -43.68% | -49.93% | -65.51% | -47.21% | +14.97% |